Police & Firemen s Retirement System of New Jersey Sells 777 Shares of Apogee Therapeutics Inc. $APGE

Police & Firemen s Retirement System of New Jersey reduced its position in shares of Apogee Therapeutics Inc. (NASDAQ:APGE) by 9.6% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,349 shares of the company’s stock after selling 777 shares during the quarter. Police & Firemen s Retirement System of New Jersey’s holdings in Apogee Therapeutics were worth $319,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in APGE. Nisa Investment Advisors LLC raised its stake in shares of Apogee Therapeutics by 99.2% during the second quarter. Nisa Investment Advisors LLC now owns 769 shares of the company’s stock valued at $33,000 after acquiring an additional 383 shares during the last quarter. Brooklyn Investment Group purchased a new position in Apogee Therapeutics during the 1st quarter valued at about $42,000. AlphaQuest LLC bought a new position in Apogee Therapeutics during the 1st quarter valued at approximately $43,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Apogee Therapeutics by 18.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,779 shares of the company’s stock worth $77,000 after buying an additional 272 shares during the period. Finally, Allspring Global Investments Holdings LLC purchased a new stake in Apogee Therapeutics in the 2nd quarter worth approximately $218,000. Institutional investors own 79.04% of the company’s stock.

Insider Activity at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 10,785 shares of the business’s stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $55.07, for a total value of $593,929.95. Following the completion of the transaction, the insider directly owned 282,008 shares in the company, valued at $15,530,180.56. The trade was a 3.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael Thomas Henderson sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $63.01, for a total value of $1,260,200.00. Following the completion of the transaction, the chief executive officer directly owned 1,272,987 shares in the company, valued at $80,210,910.87. This trade represents a 1.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 38,620 shares of company stock valued at $2,160,704 in the last three months. 42.77% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Craig Hallum began coverage on Apogee Therapeutics in a research note on Monday, November 3rd. They issued a “buy” rating and a $109.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apogee Therapeutics in a research report on Wednesday, October 8th. Mizuho initiated coverage on shares of Apogee Therapeutics in a research report on Tuesday, October 21st. They set an “outperform” rating and a $105.00 price target on the stock. Citigroup reissued a “buy” rating on shares of Apogee Therapeutics in a research note on Thursday, August 28th. Finally, Wedbush reaffirmed an “outperform” rating and set a $90.00 price objective on shares of Apogee Therapeutics in a research report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $98.38.

Apogee Therapeutics Price Performance

Shares of NASDAQ:APGE opened at $70.39 on Thursday. The business has a fifty day moving average price of $52.75 and a 200-day moving average price of $43.88. The company has a market capitalization of $4.81 billion, a PE ratio of -16.07 and a beta of 1.50. Apogee Therapeutics Inc. has a 1-year low of $26.20 and a 1-year high of $73.90.

Apogee Therapeutics (NASDAQ:APGE) last announced its quarterly earnings data on Monday, November 10th. The company reported ($1.11) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.03. On average, sell-side analysts anticipate that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current fiscal year.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.